1. Home
  2. SNEX vs PCVX Comparison

SNEX vs PCVX Comparison

Compare SNEX & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo StoneX Group Inc.

SNEX

StoneX Group Inc.

HOLD

Current Price

$65.97

Market Cap

8.4B

Sector

Finance

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

N/A

Current Price

$65.96

Market Cap

7.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNEX
PCVX
Founded
1924
2013
Country
United States
United States
Employees
5400
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4B
7.0B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
SNEX
PCVX
Price
$65.97
$65.96
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $108.67
AVG Volume (30 Days)
754.2K
★ 1.8M
Earning Date
11-23-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 3.49
N/A
Revenue
★ $132,378,200,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.29
★ N/A
Revenue Growth
★ 32.53
N/A
52 Week Low
$63.25
$39.87
52 Week High
$141.99
$90.75

Technical Indicators

Market Signals
Indicator
SNEX
PCVX
Relative Strength Index (RSI) 43.56 58.82
Support Level $64.53 $52.91
Resistance Level $71.09 N/A
Average True Range (ATR) 2.53 4.04
MACD 0.22 0.98
Stochastic Oscillator 36.70 30.10

Price Performance

Historical Comparison
SNEX
PCVX

About SNEX StoneX Group Inc.

StoneX Group Inc is a brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: